CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗的护理考量：细胞因子释放综合征与免疫效应细胞相关神经毒性综合征的管理
英文原题：Nursing Considerations for CAR T-Cell Therapy: Management of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome.
查看英文原题
Nursing Considerations for CAR T-Cell Therapy: Management of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究思路按摘要原文分段
背景
嵌合抗原受体（CAR）T细胞疗法是治疗某些血液系统恶性肿瘤的一种有前景的方法，但许多护士未接受过护理两种常见副作用——细胞因子释放综合征（CRS）和免疫效应细胞相关神经毒性综合征（ICANS）的培训。
目的
本文提供CRS和ICANS的基础知识，包括肿瘤科护士在毒性监测、护理协调和患者教育中的作用。
方法
为支持安全、循证的CAR-T 细胞治疗实施，本文讨论了CRS和ICANS的分级指南、护理评估、干预措施及教育策略。
结果
护士通过早期识别、持续监测、治疗干预以及患者和照护者教育，在减轻CRS和ICANS方面发挥关键作用。使用标准化方案、频繁监测生命体征并进行神经系统评估，可优化患者安全和结局。
展开英文摘要原文
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy is a promising treatment for certain hematologic malignancies, but many nurses are not trained in caring for two common side effects, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
OBJECTIVES
This article provides foundational knowledge of CRS and ICANS, including the oncology nurse's role in toxicity monitoring, care coordination, and patient education.
METHODS
To support safe, evidence-based CAR T-cell therapy administration, this article discusses grading guidelines, nursing assessments, interventions, and education strategies for CRS and ICANS.
FINDINGS
Nurses serve a key role in mitigating CRS and ICANS through early recognition, continuous monitoring, therapeutic intervention, and patient and caregiver education. Using standardized protocols, frequently monitoring vital signs, and performing neurologic assessments optimize patient safety and outcomes.
论文信息
- 作者
- Miller DM
- 单位
- Demi M. Miller.
- 期刊
- Clinical journal of oncology nursing2026 Jul 8
- 原文标识
- PubMed 42462106 · DOI 10.1188/26.CJON.S2.E67-E72